HomeCompareISDS vs MRK

ISDS vs MRK: Dividend Comparison 2026

ISDS yields 9.19% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ISDS wins by $6.0K in total portfolio value
10 years
ISDS
ISDS
● Live price
9.19%
Share price
$21.77
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36.7K
Annual income
$1,639.60
Full ISDS calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — ISDS vs MRK

📍 ISDS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodISDSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ISDS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ISDS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ISDS
Annual income on $10K today (after 15% tax)
$781.04/yr
After 10yr DRIP, annual income (after tax)
$1,393.66/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, ISDS beats the other by $585.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ISDS + MRK for your $10,000?

ISDS: 50%MRK: 50%
100% MRK50/50100% ISDS
Portfolio after 10yr
$33.7K
Annual income
$1,294.95/yr
Blended yield
3.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ISDS
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ISDS buys
0
MRK buys
0
No recent congressional trades found for ISDS or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricISDSMRK
Forward yield9.19%3.25%
Annual dividend / share$2.00$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$36.7K$30.7K
Annual income after 10y$1,639.60$950.29
Total dividends collected$12.8K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ISDS vs MRK ($10,000, DRIP)

YearISDS PortfolioISDS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,619$918.87$11,192$351.54+$427.00ISDS
2$13,430$997.78$12,524$392.70+$906.00ISDS
3$15,448$1,077.86$14,015$438.65+$1.4KISDS
4$17,688$1,158.70$15,682$489.96+$2.0KISDS
5$20,166$1,239.93$17,547$547.23+$2.6KISDS
6$22,899$1,321.16$19,632$611.16+$3.3KISDS
7$25,904$1,402.05$21,963$682.53+$3.9KISDS
8$29,199$1,482.28$24,571$762.18+$4.6KISDS
9$32,805$1,561.55$27,486$851.08+$5.3KISDS
10$36,741$1,639.60$30,745$950.29+$6.0KISDS

ISDS vs MRK: Complete Analysis 2026

ISDSStock

The investment seeks to track the investment results (before fees and expenses) of the Invesco Strategic Developed ex-US Small Company Index (the "underlying index"). The fund generally will invest at least 80% of its total assets in securities that comprise the underlying index and American depositary receipts ("ADRs") and global depositary receipts ("GDRs") that are based on securities in the underlying index. The underlying index is designed to measure the performance of equity securities issued by higher quality, small-business-sized companies located in countries designated as developed market countries (excluding the U.S.). The fund is non-diversified.

Full ISDS Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this ISDS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ISDS vs SCHDISDS vs JEPIISDS vs OISDS vs KOISDS vs MAINISDS vs JNJISDS vs ABBVISDS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.